More Divestments In Store As Takeda Digests Shire, Faces Expiries

Takeda remains committed to meeting its post-Shire divestment target, as it faces up to $2bn in at-risk revenues from expiries and seeks additional cost synergies. 

Takeda
Divestments, Expiries, Cost Savings On The Cards For Takeda • Source: Shutterstock

While Takeda Pharmaceutical Co. Ltd. is "very pleased" with the recent deal to sell Xiidra to Novartis AG, "there will be more to come" as the Japanese firm continues to rationalize assets after the Shire PLC acquisition, CEO Christophe Weber says.

The deal for ex-Shire dry eye drug Xiidra (lifitegrast) is worth up to $5.3bn in total to Takeda, which has...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.